NDC 70771-1674

Roflumilast

Roflumilast

Roflumilast is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Cadila Healthcare Limited. The primary component is Roflumilast.

Product ID70771-1674_17412ffc-3fe3-4503-a5d4-65f3421da18d
NDC70771-1674
Product TypeHuman Prescription Drug
Proprietary NameRoflumilast
Generic NameRoflumilast
Dosage FormTablet
Route of AdministrationORAL
Marketing Start Date2022-10-03
Marketing CategoryANDA /
Application NumberANDA208303
Labeler NameCadila Healthcare Limited
Substance NameROFLUMILAST
Active Ingredient Strength500 ug/1
Pharm ClassesPhosphodiesterase 4 Inhibitor [EPC], Phosphodiesterase 4 Inhibitors [MoA]
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 70771-1674-3

30 TABLET in 1 BOTTLE (70771-1674-3)
Marketing Start Date2022-10-03
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "Roflumilast" or generic name "Roflumilast"

NDCBrand NameGeneric Name
0378-1905RoflumilastRoflumilast
13668-476RoflumilastRoflumilast
31722-623RoflumilastRoflumilast
42571-259ROFLUMILASTRoflumilast
43547-005ROFLUMILASTroflumilast
64380-786roflumilastROFLUMILAST
68382-969RoflumilastRoflumilast
70771-1674RoflumilastRoflumilast
72205-200RoflumilastRoflumilast
72205-201RoflumilastRoflumilast
80610-130roflumilastroflumilast
0310-0088Daliresproflumilast
0310-0095Daliresproflumilast
55154-4625Daliresproflumilast

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.